Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses next steps regarding treatments for patients with ovarian cancer. Combinations of PARP inhibitors with other DNA repair agents or even with immunotherapy has started to interest researchers.
Real-World Data Supports Avelumab Use for Locally Advanced, Metastatic Urothelial Carcinoma
February 20th 2023Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.
Read More
Vedolizumab and Standard Prophylaxis Proves Effective in Preventing GI aGVHD
February 19th 2023The phase 3 GRAPHITE study showed that vedolizumab plus standard prophylaxis after unrelated allogeneic hematopoietic stem cell transplantation was more effective vs placebo for the prevention of lower gastrointestinal graft-vs-host disease.
Read More
Iomab-B Shows Significant Improvement in R/R AML Over Chemotherapy Prior to Allogeneic HCT
February 19th 2023In findings from the phase 3 SIERRA trial, Iomab-B-based conditioning for patients with relapsed or refractory acute myeloid leukemia provided significant efficacy and tolerable safety results over the current standard of care.
Read More
2 Clarke Drive
Cranbury, NJ 08512